公开(公告)号：WO9851824A9

公开(公告)日：1999-04-01

申请号：PCT/US9809972

申请日：1998-05-15

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEPHEN D

IPC: C07K14/47 ,  C07K16/18 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/68 ,  G01N33/574

CPC classification number: C07K16/18 ,  C07K14/47 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/6893 ,  G01N2800/348

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as UT116 and transcribed from urinary tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary tract cancer. Also provided are antibodies which specifically bind to UT116-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific UT116 polypeptide, which molecules are useful for the therapeutic treatment of urinary tract diseases, tumors or metastases.

Abstract translation: 描述了一组连续和部分重叠的cDNA序列和由此编码的多肽，其被命名为UT116并从尿道组织转录。 这些序列可用于检测，诊断，分期，监测，预后，体内成像，预防或治疗或确定个体对泌尿道疾病和病症如尿道癌的倾向。 还提供了特异性结合UT116编码的多肽或蛋白质的抗体，以及预防组织特异性UT116多肽的作用的激动剂或抑制剂，该分子可用于治疗尿路疾病，肿瘤或转移瘤。

公开(公告)号：CA2232237C

公开(公告)日：2011-10-18

申请号：CA2232237

申请日：1997-08-19

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEPHEN D

IPC: C12N15/12 ,  G01N33/53 ,  A61K31/70 ,  A61K39/00 ,  A61K48/00 ,  C07H21/00 ,  C07K14/47 ,  C07K14/82 ,  C07K16/18 ,  C07K16/30 ,  C12N5/00 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/68 ,  C12R1/91 ,  G01N33/543 ,  G01N33/574

Abstract: A novel member of the uteroglobin family of proteins, designated as BU101, is described. BU101 is defined by a set of contiguous and partially overlapping RNA sequences transcribed from breast tissue, and polypeptides encoded thereby. A fully sequenced clone representing the longest continuous sequence of BU101 is also disclosed. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BU101-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BU101 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.

公开(公告)号：AU1457901A

公开(公告)日：2001-05-14

申请号：AU1457901

申请日：2000-11-02

Applicant: ABBOTT LAB

Inventor： RUSSELL JOHN C ,  GRANADOS EDWARD N

IPC: G01N21/78 ,  C12Q1/26 ,  C12Q1/28 ,  C12Q1/32 ,  C12Q1/37 ,  C12Q1/44 ,  C12Q1/48 ,  C12Q1/527 ,  C12Q1/00

公开(公告)号：CA2307716A1

公开(公告)日：1999-05-06

申请号：CA2307716

申请日：1998-10-28

Applicant: ABBOTT LAB

Inventor： HODGES STEVEN C ,  STROUPE STEPHEN D ,  KLASS MICHAEL R ,  BILLING-MEDEL PATRICIA A ,  FRIEDMAN PAULA N ,  COHEN MAURICE ,  YU HONG ,  COLPITTS TRACEY L ,  RUSSELL JOHN C ,  GRANADOS EDWARD N ,  GORDON JULIAN ,  KRATOCHVIL JON D

IPC: C07K14/47 ,  C12N9/64 ,  C12Q1/68 ,  G01N33/574

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BS247 and transcribed from breast tissue, are described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer. Also provided are antibodies which specifically bind to BS247-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BS247 polypeptides, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.

公开(公告)号：CA2292759A1

公开(公告)日：1998-12-10

申请号：CA2292759

申请日：1998-06-05

Applicant: ABBOTT LAB

Inventor： GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  ROBERTS-RAPP LISA ,  KRATOCHVIL JON D ,  FRIEDMAN PAULA N ,  RUSSELL JOHN C ,  STROUPE STEPHEN D ,  YU HONG ,  BILLING-MEDEL PATRICIA A ,  COLPITTS TRACEY L ,  COHEN MAURICE

IPC: G01N33/53 ,  C07K14/47 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/566 ,  G01N33/574 ,  C12N5/12

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BL172 and transcribed from urinary tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary tract cancer. Also provided are antibodies which specifically bind to BL172-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissuespecific BL172 polypeptide, which molecules are useful for the therapeutic treatment of urinary tract diseases, tumors or metastases.

公开(公告)号：CA2269634A1

公开(公告)日：1998-05-07

申请号：CA2269634

申请日：1997-10-31

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  RUSSELL JOHN C ,  STROUPE STEVEN D ,  GORDON JULIAN ,  FRIEDMAN PAULA N ,  KRATOCHVIL JON D ,  KLASS MICHAEL R ,  COLPITTS TRACEY L ,  COHEN MAURICE ,  ROBERTS-RAPP LISA

IPC: G01N33/53 ,  A61K38/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/47 ,  C07K16/30 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/68 ,  C12N15/63 ,  A61K38/17 ,  G01N33/574 ,  G01N33/577

Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as BS106 and transcribed from breast tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BS106-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BS106 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.

公开(公告)号：CA2250706A1

公开(公告)日：1997-11-06

申请号：CA2250706

申请日：1997-04-25

Applicant: ABBOTT LAB

Inventor： GRANADOS EDWARD N ,  SOLOMON NATALIE A ,  BOUMA STANLEY R ,  CARRINO JOHN J

IPC: C12N15/09 ,  C12Q1/68

Abstract: Provided herein are methods for detecting multiple target nucleic acid sequences in a test sample. Also provided is a hybridization platform useful for detecting multiple target sequences in a test sample. The hybridization platform comprises a solid support material having a defined pattern of capture probes immobilized thereon.

公开(公告)号：CA2167931A1

公开(公告)日：1995-03-02

申请号：CA2167931

申请日：1994-08-22

Applicant: ABBOTT LAB

Inventor： GRANADOS EDWARD N ,  CHOW HERBERT S ,  HEIMAN DANIEL F ,  THALER MARIA L

IPC: C12N5/06 ,  G01N33/50 ,  G01N33/543 ,  G01N33/554 ,  G01N33/556 ,  G01N33/569 ,  G01N33/557 ,  G01N33/564

Abstract: A method is provided for the preparation of semisolid particles or cells that have been chemically derivatized resulting in hydrazide functionalities covalently incorporated onto cell surface membrane molecules of the semisolid particles or cells, as well as a method for determining the levels of hydrazide groups on the particles or cells. The method involves the preparation and analysis of red blood cells chemically derivatized in such a manner that hydrazide functionalities have been covalently incorporated onto the cell membrane molecules, the preparation of hydrazine derivatized cells and the use thereof of the novel cells in agglutination reactions to promote the attachment of antigens and antibodies to the hydrazine derivatized cells without loss of antibody activity or the blocking of the epitope of interest.

公开(公告)号：CA2399047C

公开(公告)日：2011-04-19

申请号：CA2399047

申请日：2001-02-28

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N ,  HODGES STEVEN C ,  KLASS MICHAEL R ,  KRATOCHVIL JON D ,  ROBERTS-RAPP LISA ,  RUSSELL JOHN C ,  STROUPE STEVEN D

IPC: C12N15/12 ,  G01N33/53 ,  C07H21/00 ,  C07K14/47 ,  C07K16/18 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/574

Abstract: Multimeric polypeptides antigens comprising polypeptides designated as BS106 and transcribed from breast tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring prognosticating or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BS106-encoded polypeptide or protein.

公开(公告)号：ES2343103T3

公开(公告)日：2010-07-23

申请号：ES00903373

申请日：2000-01-21

Applicant: ABBOTT LAB

Inventor： BILLING-MEDEL PATRICIA A ,  COHEN MAURICE ,  COLPITTS TRACEY L ,  FRIEDMAN PAULA N ,  GORDON JULIAN ,  GRANADOS EDWARD N

IPC: C07K14/47 ,  G01N33/53 ,  C07K16/18 ,  C07K16/30 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63 ,  C12P21/02 ,  C12Q1/68 ,  C12Q1/6886 ,  G01N33/566 ,  G01N33/574 ,  G01N33/577 ,  G01N37/00

Abstract: Un método de detección de cáncer de mama en un individuo, comprendiendo dicho método: (a) poner en contacto una muestra de ensayo sospechosa de contener polinucleótido diana de dicho individuo con al menos un oligonucleótido que tenga una longitud de 15 a 50 nucleótidos y que tenga una identidad de al menos el 90% con un polinucleótido seleccionado del grupo que consisten en las SECUENCIAS ID Nº 1-9 y complementarias de las mismas, donde la muestra de ensayo se selecciona del grupo que consiste en sangre completa, suero, plasma, líquido cefalorraquídeo, esputo, lavado bronquial, aspirados bronquiales, orina, fluidos linfáticos, secreciones externas de los tractos respiratorio, intestinal y genitourinario, lágrimas, saliva y heces; (b) detectar la presencia de polinucleótidos diana de la muestra de ensayo que se unen a dicho oligonucleótido, cuya detección indica cáncer mama.